Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Prospective Phase III Clinical Trial of EBV-DNA-Guided Adaptive Immunotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

NCT07238569 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07238569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07238569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Prospective Phase III Clinical Trial of EBV-DNA-Guided Adaptive Immunotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 1, 2025
Completion date
May 23, 2031
Enrollment
516 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharangeal cancer, nasopharyngeal cancinoma (npc)